Effects of Transdermal Fentanyl Treatment on Acute Pain and Inflammation in Rats with Adjuvant-induced Monoarthritis

Comp Med. 2022 Oct 1;72(5):320-329. doi: 10.30802/AALAS-CM-21-000066. Epub 2022 Oct 13.

Abstract

Eliminating unnecessary pain is an important requirement of performing animal experimentation, including reducing and controlling pain of animals used in pain research. The goal of this study was to refine an adjuvant-induced monoarthritis model in rats by providing analgesia with a transdermal fentanyl solution (TFS). Male and female Sprague-Dawley rats, single- or pair-housed, were injected with 20 μL of complete Freund adjuvant (CFA) into the left ankle joint. CFA-injected rats treated with a single dose of transdermal fentanyl solution (0.33 or 1 mg/kg) were compared with an untreated CFA-injected group and sham groups that received either no treatment or TFS treatment (1 mg/kg) during 72 h. At the tested doses, TFS reduced mechanical hyperalgesia and improved the mobility, stance, rearing, and lameness scores at 6 h after CFA injection. Joint circumferences were not reduced by TFS treatment, and no significant differences were detected between the 2 doses of TFS, or between single- and pair-housed rats. Treatment with TFS did not appear to interfere with model development and characteristics. However, overall, the analgesic effect was transient, and several opioid-related side effects were observed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Pain*
  • Adjuvants, Immunologic
  • Analgesics, Opioid / pharmacology
  • Animals
  • Female
  • Fentanyl* / adverse effects
  • Freund's Adjuvant
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Male
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Freund's Adjuvant
  • Fentanyl
  • Analgesics, Opioid
  • Adjuvants, Immunologic